<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114229</article-id><article-id pub-id-type="publisher-id">ACM-41622</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_67771947.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  多囊卵巢综合征与代谢综合征相关性研究进展
  Research Progress on the Correlation between Polycystic Ovary Syndrome and Metabolic Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>叶美</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>永林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>大理大学临床医学院，云南 大理</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1597</fpage><lpage>1600</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    多囊卵巢综合征(polycystic ovarian syndrome, PCOS)，是一种多见于青春期起病的妇科内分泌疾病。而代谢综合征(metabolic syndrome, MS)是一组以人体蛋白质、脂肪、碳水化合物等物质发生代谢紊乱的复杂代谢症候群。MS和PCOS都是育龄期女性的常见疾病，都可伴有肥胖和胰岛素抵抗(RI)，所以将MS和PCOS结合起来研究时，二者重叠的部分最有研究价值。随着PCOS研究的深入，其发病机制有了新的进展，且与MS密切相关。更具体地说，与同年龄的普通人群相比，PCOS患者MS的发病率更高。所以研究PCOS与MS的相关性，对于后期我们在诊断、治疗和预防PCOS患者发生MS方面有重要意义。本文就PCOS与MS的相关性作一综述。
    Polycystic ovarian syndrome (PCOS) is one of the common gynecological endocrine diseases. The onset of disease is more common in adolescence, characterized by high androgen clinical or biochemical manifestations, persistent anovulation, ovarian polycystic changes, often accompanied by insulin resistance and obesity. And metabolic syndrome (MS) refers to the pathological state of metabolic disorder of protein, fat, carbohydrate and other substances in human body, which is a group of complex metabolic syndrome. At the heart of MS is obesity and insulin resistance. MS and PCOS are common diseases in women of childbearing age, and when MS and PCOS are combined to study, the most valuable part is the overlap between them. With the deepening of PCOS research, its pathogenesis has made new progress and is closely related to MS. More specifically, the incidence of MS in PCOS patients is higher than in the general population of the same age. Therefore, the study of the correlation between PCOS and MS is of great significance to the later diagnosis, treatment and prevention for MS patients. 
  
 
</p></abstract><kwd-group><kwd>多囊卵巢综合征，代谢综合征，相关性, Polycystic Ovarian Syndrome</kwd><kwd> Metabolic Syndrome</kwd><kwd> Correlation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>多囊卵巢综合征(polycystic ovarian syndrome, PCOS)，是一种多见于青春期起病的妇科内分泌疾病。而代谢综合征(metabolic syndrome, MS)是一组以人体蛋白质、脂肪、碳水化合物等物质发生代谢紊乱的复杂代谢症候群。MS和PCOS都是育龄期女性的常见疾病，都可伴有肥胖和胰岛素抵抗(RI)，所以将MS和PCOS结合起来研究时，二者重叠的部分最有研究价值。随着PCOS研究的深入，其发病机制有了新的进展，且与MS密切相关。更具体地说，与同年龄的普通人群相比，PCOS患者MS的发病率更高。所以研究PCOS与MS的相关性，对于后期我们在诊断、治疗和预防PCOS患者发生MS方面有重要意义。本文就PCOS与MS的相关性作一综述。</p></sec><sec id="s2"><title>关键词</title><p>多囊卵巢综合征，代谢综合征，相关性</p></sec><sec id="s3"><title>Research Progress on the Correlation between Polycystic Ovary Syndrome and Metabolic Syndrome</title><p>Yemei Yang, Yonglin Yang<sup>*</sup></p><p>School of Clinical Medicine, Dali University, Dali Yunnan</p><p><img src="//html.hanspub.org/file/22-1572084x5_hanspub.png" /></p><p>Received: Mar. 12<sup>th</sup>, 2021; accepted: Apr. 9<sup>th</sup>, 2021; published: Apr. 16<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/22-1572084x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Polycystic ovarian syndrome (PCOS) is one of the common gynecological endocrine diseases. The onset of disease is more common in adolescence, characterized by high androgen clinical or biochemical manifestations, persistent anovulation, ovarian polycystic changes, often accompanied by insulin resistance and obesity. And metabolic syndrome (MS) refers to the pathological state of metabolic disorder of protein, fat, carbohydrate and other substances in human body, which is a group of complex metabolic syndrome. At the heart of MS is obesity and insulin resistance. MS and PCOS are common diseases in women of childbearing age, and when MS and PCOS are combined to study, the most valuable part is the overlap between them. With the deepening of PCOS research, its pathogenesis has made new progress and is closely related to MS. More specifically, the incidence of MS in PCOS patients is higher than in the general population of the same age. Therefore, the study of the correlation between PCOS and MS is of great significance to the later diagnosis, treatment and prevention for MS patients.</p><p>Keywords:Polycystic Ovarian Syndrome, Metabolic Syndrome, Correlation</p><disp-formula id="hanspub.41622-formula18"><graphic xlink:href="//html.hanspub.org/file/22-1572084x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1572084x8_hanspub.png" /> <img src="//html.hanspub.org/file/22-1572084x9_hanspub.png" /></p></sec><sec id="s5"><title>1. PCOS及MS的诊断</title><sec id="s5_1"><title>1.1. PCOS诊断</title><p>自1935年Stein和Leventhal首次报道PCOS这一疾病以来，国际上先后出现了3个诊断共识，分别是美国国立卫生研究院(NIH)提出的NIH标准、欧洲生殖和胚胎医学会(ESHRE)与美国生殖医学会(ASRM)提出的AES标准及2011年中华医学会妇科内分泌学组制定的中国PCOS的诊断标准 [<xref ref-type="bibr" rid="hanspub.41622-ref1">1</xref>]。目前较多采用的诊断是欧洲生殖和胚胎医学会(ESHRE)与美国生殖医学会(ASRM) 2003年提出的鹿特丹标准：①稀发排卵或无排卵。②具有高雄激素血症和(或)高雄激素的临床表现。③多囊卵巢的超声表现(一侧或双侧卵巢有12个以上直径为2~9 mm的卵泡，和/或卵巢体积大于10 ml)。④3项中符合2条，并排除先天性肾上腺皮质增生、库欣综合征、分泌雄激素的肿瘤等疾病。该标准提出PCOS是一种卵巢功能异常性疾病，其核心特点为雄激素过度升高和多囊卵巢(PCO)。PCOS患者不仅可以有月经异常、肥胖和高雄激素等症状，而且其发生2型糖尿病风险明显增加 [<xref ref-type="bibr" rid="hanspub.41622-ref2">2</xref>]。</p></sec><sec id="s5_2"><title>1.2. MS诊断</title><p>目前我国主要采用的是中华医学会糖尿病分会(CDS, 2004)建议的MS诊断标准：①超重和(或)肥胖BMI ≥ 25 kg/m<sup>2</sup>。②血糖异常：空腹血糖(FPG) ≥ 6.1 mmol/L (110 mg/dl)和(或) OGTT 2小时血糖值(2 h PG) ≥ 7.8 mmol/L (140 mg/dl)，和(或)已确诊糖尿病并治疗者。③血压升高：收缩压/舒张压≥ 140/90 mmHg，和(或)已确诊高血压并治疗者。④血症异常：空腹血甘油三酯(TG) ≥ 1.7 mmol/L (150 mg/dl)，和(或)空腹血高密度脂蛋白胆固醇(HDL-C) &lt; 0.9 mmol/L (35 mg/dl) (男)，&lt;1.0 mmol/L (39 mg/dl) (女)。具备3项及以上标准则代谢综合征可确诊 [<xref ref-type="bibr" rid="hanspub.41622-ref3">3</xref>]。目前研究认为，胰岛素抵抗(IR)是MS的主要发病机制之一，而肥胖，尤其是中心性肥胖与胰岛素抵抗的发生关系密切。</p></sec></sec><sec id="s6"><title>2. PCOS与MS相关性因素</title><p>1、肥胖：研究表明50%以上PCOS患者肥胖(体重指数 ≥ 25 Kg/m<sup>2</sup>)，且常呈腹型肥胖(腰围/臀围 ≥ 0.80)。肥胖人群常伴有血脂异常，其高脂血症检出率远高于非肥胖人群，可高达40%。血脂异常可表现为血浆甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平的升高，高密度脂蛋白胆固醇(HDL-C)降低，这也是中心性肥胖患者的常见特征 [<xref ref-type="bibr" rid="hanspub.41622-ref4">4</xref>]。而MS的主要组成成分为肥胖，尤其是中心性肥胖。有研究显示 [<xref ref-type="bibr" rid="hanspub.41622-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41622-ref6">6</xref>] PCOS患者的MS发生率可伴随着年龄、腹围、BF、TG/HDL-C增加而明显增高，而肥胖，尤其是中心性肥胖与胰岛素的发生有密切的相关性。肥胖人群的脂肪组织增大可由于体积增大(肥大型)、细胞数量增多(增生型)、或以上两者兼具(增生肥大型)，同时伴随炎症反应如吞噬细胞和其他免疫细胞浸润，使脂肪因子分泌增多，从而出现低度的系统炎症(C反应蛋白、白介素-6、TNF-α等因子轻度升高)和胰岛素抵抗(IR)的发生。随后，胰岛素抵抗使胰岛素作用的靶器官对葡萄糖的利用发生障碍，从而导致高血糖，糖异生减少，脂肪量增加，进一步加重腹部脂肪聚集，形成恶性循环 [<xref ref-type="bibr" rid="hanspub.41622-ref7">7</xref>]。所以临床建议患有PCOS的女性在诊断后的第一年内将体重减轻5%~10%，以改善临床效果。体重减轻与代谢活性内脏脂肪的减少有关，这反过来导致降低胰岛素抵抗和优化脂质分布 [<xref ref-type="bibr" rid="hanspub.41622-ref8">8</xref>]。</p><p>2、胰岛素抵抗与高胰岛素血症：外周组织对胰岛素的敏感性降低，医学上通常称之为胰岛素抵抗(IR)，此时胰岛素的生物效能低于正常。而目前研究认为，胰岛素抵抗是MS发生的中心环节之一。在PCOS患者中约50%有不同程度的胰岛素抵抗和代偿性高胰岛素血症存在。所以胰岛素抵抗和高胰岛素血症可能是PCOS和MS的一个共同的致病机制，胰岛素抵抗和高胰岛素血症除直接影响糖脂代谢外，还通过降低性激素结合蛋白导致雄激素水平升高。由此可见，比起单纯患有PCOS的患者，同时患有PCOS和MS的患者其胰岛素抵抗和高胰岛素血症的程度更深 [<xref ref-type="bibr" rid="hanspub.41622-ref9">9</xref>]。</p><p>3、高雄激素：近年来有研究提出高雄激素是导致多囊卵巢综合征患者发生代谢综合征的一项主要因素，独立于肥胖和胰岛素抵抗 [<xref ref-type="bibr" rid="hanspub.41622-ref10">10</xref>]。PCOS患者常伴有雄激素过高的临床或生化表现。陶弢等研究 [<xref ref-type="bibr" rid="hanspub.41622-ref11">11</xref>] 显示：高雄激素PCOS女性患者发生MS的风险增加了4.29倍．而无高雄激素PCOS女性患者发生MS风险无显著增加，在校正BMI和年龄后，与非PCOS对照相比，高雄激素PCOS患者的中心性肥胖、胰岛素抵抗和高雄激素血症更加明显。由此得出以下结论：高雄激素可能增加PCOS女性患者发生MS的风险。</p><p>4、其他：除上述相关因素外，近年研究还发现血清脂联素与2型糖尿病肥胖患者的胰岛素抵抗发生负相关(r = −0.571, P = 0.01 &lt; 0.05)，脂联素降低易导致胰岛素抵抗 [<xref ref-type="bibr" rid="hanspub.41622-ref12">12</xref>]。而华飞研究 [<xref ref-type="bibr" rid="hanspub.41622-ref13">13</xref>] 指出脂质蓄积指数(lipid accumulation index, LAP)是诊断PCOS合并MS的有效指标，当LAP &gt; 54.2时具有最大敏感性和特异性。由此可见，LAP与MS密切相关，可作为一种经济、准确、简便的检测指标来判断PCOS患者是否合并MS。</p></sec><sec id="s7"><title>3. PCOS与MS相关性</title><p>近年来临床研究认为PCOS与MS密切相关，国内研究认为PCOS是患MS的风险，但这些风险可能是通过肥胖和胰岛素抵抗来介导的，单纯的PCOS并不能使MS的发生风险增高 [<xref ref-type="bibr" rid="hanspub.41622-ref14">14</xref>]。PCOS患者肥胖是导致IR的主要因素，IR所致的高胰岛素血症造成血清雄激素水平过高。高雄激素血症可加重中心性肥胖和外周组织胰岛素抵抗，导致内分泌调节紊乱而形成ＭS [<xref ref-type="bibr" rid="hanspub.41622-ref15">15</xref>]。国外也有研究表明肥胖和内脏脂肪增大在决定PCOS的最终表型中起主要作用。雄激素过多和胰岛素抵抗可能是导致代谢综合征所有特征的原因。造成这种关联的主要因素似乎与三联维生素有关，包括雄激素过多，胰岛素抵抗和相关的高胰岛素血症以及肥胖症，特别是腹部–内脏表型 [<xref ref-type="bibr" rid="hanspub.41622-ref16">16</xref>]。</p><p>综上所述，随着我国饮食结构的改变，MS有急剧上升的趋势，可能增加了PCOS的发病率。PCOS与MS之间密切相关，肥胖、胰岛素抵抗和高雄激素均可导致两者发病。多数PCOS患者有代谢紊乱问题，所以正确认识和诊断PCOS与MS、了解其相关性对后期治疗、预防PCOS与MS有重要意义，治疗MS的措施可能也是PCOS治疗的一部分。</p></sec><sec id="s8"><title>文章引用</title><p>杨叶美,杨永林. 多囊卵巢综合征与代谢综合征相关性研究进展Research Progress on the Correlation between Polycystic Ovary Syndrome and Metabolic Syndrome[J]. 临床医学进展, 2021, 11(04): 1597-1600. https://doi.org/10.12677/ACM.2021.114229</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41622-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cui, L.L. and Chen, Z.J. (2011) Diagnosis Criteria and Guidelines for the Diagnosis and Treatment of PCOS. Journal of International Reproductive Health/Family Planning, 30, 405-408.</mixed-citation></ref><ref id="hanspub.41622-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">宋颖, 李蓉. 多囊卵巢综合征中国诊疗指南解读[J]. 实用妇产科杂志, 2018, 34(10): 737-741.</mixed-citation></ref><ref id="hanspub.41622-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会糖尿病分会代谢综合征研究协作组. 中华医学会糖尿病分会关于MS的建议[J]. 中华糖尿病杂志, 2004, 12(3): 156-161.</mixed-citation></ref><ref id="hanspub.41622-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">窦京涛, 孙启虹. 肥胖、胰岛素抵抗与代谢综合征[J]. 内科理论与实践, 2012, 7(4): 241-244.</mixed-citation></ref><ref id="hanspub.41622-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">苏丹, 祈冰, 侯丽辉, 等. 多囊卵巢综合征与代谢综合征[J]. 医学研究杂志, 2012, 41(3): 9-11.</mixed-citation></ref><ref id="hanspub.41622-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J. and Huang, W. (2018) Analysis of Related Factors of Polycystic Ovary Syndrome and Metabolic Syndrome. Sichuan Medical Journal, 39, 305-308.</mixed-citation></ref><ref id="hanspub.41622-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">陈丽, 郝丽娟. 脂代谢异常与多囊卵巢综合征[J]. 生殖医学杂志, 2019(28): 836-839.</mixed-citation></ref><ref id="hanspub.41622-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chandrasekaran, S. and Sagili, H. (2018) Metabolic Syndrome in Women with Polycystic Ovary Syndrome. The Obstetrician &amp; Gynaecologist, 20, 245-252. ://doi.org/10.1111/tog.12519</mixed-citation></ref><ref id="hanspub.41622-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">高姗姗, 李媛. 多囊卵巢综合征与代谢综合征的关系[J]. 中华妇产科杂志, 2008, 43(2): 152-153.</mixed-citation></ref><ref id="hanspub.41622-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王歆. 多囊卵巢综合征与代谢综合征的相关性研究[J]. 医药前沿, 2013(15): 123-124.</mixed-citation></ref><ref id="hanspub.41622-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tao, T., Liu, W. Zhao, A., Li, S.X., Zheng, J., Wang, L., Zhou, J., Wang, R. and Zhang, P. (2013) Morbidity and Risk Factors of Metabolic Syndrome in Different Phenotypes of Polycystic Ovary Syndrome. Chinese Journal of Endocrinology and Metabolism, 29, 200-205.</mixed-citation></ref><ref id="hanspub.41622-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Cai, Y., Bai, Y., et al. (2016) Correlation Research between Serum Adiponectin, Insulin Resistance and Metabolic Syndrome. China Practical Medical, 11, 8-10.</mixed-citation></ref><ref id="hanspub.41622-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hua, F. (2016) Study and Assessment of Insulin Resistance, Metabolic Syndrome and Depression in Women with Polycystic Ovary Syndrome. Soochow University, Suzhou, 1-78.</mixed-citation></ref><ref id="hanspub.41622-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yan, Q., Hong, F., Gu, W., Zhang, Y.C., Zhang, Y.W., Shi, J., Wang, W., Li, X. and Ning, G. (2010) Study on the Risk of Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Chinese Journal of Endocrinology and Metabolism, 26, 351-354.</mixed-citation></ref><ref id="hanspub.41622-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tian, X., Hou, L., Ge, J. and Liu, Y. (2015) Progress of Relationship, Prophylaxis and Therapy of Polycystic Ovary Syndrome and Metabolic Syndrome. Chinese Journal of Obstetrics &amp; Gynecology and Pediatrics (Electronic Edition), 11, 114-116.</mixed-citation></ref><ref id="hanspub.41622-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pasquali, R. (2018) Metabolic Syndrome in Polycystic Ovary Syndrome. Metabolic Syndrome Consequent to Endocrine Disorders. Frontiers of Hormone Research, 49, 114-130. ://doi.org/10.1159/000485995</mixed-citation></ref></ref-list></back></article>